The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.
I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.
A new study shows first-time proof that AI can detect the severity of diabetic macular edema, which is a leading cause of blindness.
The U.S. FDA declined to approve a pre-filled syringe version of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea.
Regeneron Pharmaceuticals announced positive top-line data from the Phase III PANORAMA study of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Genentech announced encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.
Momenta Pharmaceuticals and Mylan plan to begin a pivotal clinical study of a biosimilar to Regeneron’s blockbuster eye drug Eylea in first-half 2018.
KalVista Pharmaceuticals Inc. inked a collaboration deal with Merck & Co. for potential therapeutic treatments for diabetic macular edema.
Roche was granted an exclusive, worldwide license to develop and commercialize all IL-6 antagonist antibody technology owned by Eleven Biotherapeutics.